Supraventricular tachycardias

Active Ingredient: Verapamil

Indication for Verapamil

Population group: only minors (0 - 18 years old) , adults (18 years old or older)
Therapeutic intent: Preventive action

Supraventricular tachycardias such as paroxysmal supraventricular tachycardia, atrial fibrillation/flutter with rapid ventricular response (except in WPW syndrome or LGL syndrome).

For this indication, competent medicine agencies globally authorize below treatments:

40-120 mg 3-4 times daily

For:

Dosage regimens

Oral, between 40 milligrams verapamil and 120 milligrams verapamil, 3 to 4 times daily to meals. The maximum allowed total dose is 480 milligrams verapamil daily.

Detailed description

In cases of supraventricular tachycardia the usual dose is 40 mg to 120 mg 3 to 4 times daily according to the severity of the patient’s condition.

Dosage considerations

Verapamil should be taken preferably with or shortly after meals.

Verapamil should not be taken with grapefruit juice.

For patients up to 2 years old 20 mg 2-3 times daily and for patients >2 years old 40-120 mg 2-3 times daily

For:

Dosage regimens

Regimen A: In case that patient age in years is ≤ 2, oral, 20 milligrams verapamil, 2 to 3 times daily to meals. The maximum allowed total dose is 360 milligrams verapamil daily.

Regimen B: In case that patient age in years is ≥ 2, oral, between 40 milligrams verapamil and 120 milligrams verapamil, 2 to 3 times daily to meals. The maximum allowed total dose is 360 milligrams verapamil daily.

Detailed description

Up to 2 years: 20 mg, 2-3 times a day.

2 years and above: 40-120 mg, 2-3 times a day, according to age and effectiveness.

Dosage considerations

Verapamil should be taken preferably with or shortly after meals.

Verapamil should not be taken with grapefruit juice.

Active ingredient

Verapamil

Verapamil inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cell. The myocardial oxygen demand is lowered directly as a result of the effect on the energy consuming metabolic processes of the myocardial cell and indirectly due to a reduction of the afterload. Due to its effect on coronary vascular smooth muscle, verapamil enhances myocardial blood flow, even in post‐stenotic areas, and relieves coronary spasms. These properties contribute to the anti‐ischaemic and antianginal efficacy of verapamil in all types of coronary artery disease.

Read more about Verapamil

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.